Hajduk PJ - Search Results

1

NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.

Hajduk PJ, Shuker SB, Nettesheim DG, Craig R, Augeri DJ, Betebenner D, Albert DH, Guo Y, Meadows RP, Xu L, Michaelides M, Davidsen SK, Fesik SW. Hajduk PJ, et al. J Med Chem. 2002 Dec 19;45(26):5628-39. doi: 10.1021/jm020160g. J Med Chem. 2002. PMID: 12477346

2

NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter.

Huth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B, Braddock DT, Muchmore SW, Comess KM, Fesik SW, Clore GM, Levens D, Hajduk PJ. Huth JR, et al. Among authors: hajduk pj. J Med Chem. 2004 Sep 23;47(20):4851-7. doi: 10.1021/jm0497803. J Med Chem. 2004. PMID: 15369388

3

Druggability indices for protein targets derived from NMR-based screening data.

Hajduk PJ, Huth JR, Fesik SW. Hajduk PJ, et al. J Med Chem. 2005 Apr 7;48(7):2518-25. doi: 10.1021/jm049131r. J Med Chem. 2005. PMID: 15801841

4

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.

Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, Nettesheim DG, Rosenberg SH, Shen W, Thomas S, Wang X, Zanze I, Zhang H, Fesik SW. Petros AM, et al. Among authors: hajduk pj. J Med Chem. 2006 Jan 26;49(2):656-63. doi: 10.1021/jm0507532. J Med Chem. 2006. PMID: 16420051

5

Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.

Gracias V, Ji Z, Akritopoulou-Zanze I, Abad-Zapatero C, Huth JR, Song D, Hajduk PJ, Johnson EF, Glaser KB, Marcotte PA, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR, Djuric SW. Gracias V, et al. Among authors: hajduk pj. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2691-5. doi: 10.1016/j.bmcl.2008.03.021. Epub 2008 Mar 10. Bioorg Med Chem Lett. 2008. PMID: 18362070

6

Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B.

Liu G, Szczepankiewicz BG, Pei Z, Janowick DA, Xin Z, Hajduk PJ, Abad-Zapatero C, Liang H, Hutchins CW, Fesik SW, Ballaron SJ, Stashko MA, Lubben T, Mika AK, Zinker BA, Trevillyan JM, Jirousek MR. Liu G, et al. Among authors: hajduk pj. J Med Chem. 2003 May 22;46(11):2093-103. doi: 10.1021/jm0205696. J Med Chem. 2003. PMID: 12747781

7

Discovering high-affinity ligands for proteins: SAR by NMR.

Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Shuker SB, et al. Among authors: hajduk pj. Science. 1996 Nov 29;274(5292):1531-4. doi: 10.1126/science.274.5292.1531. Science. 1996. PMID: 8929414

8

NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein.

Hajduk PJ, Dinges J, Miknis GF, Merlock M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF, Fesik SW. Hajduk PJ, et al. J Med Chem. 1997 Sep 26;40(20):3144-50. doi: 10.1021/jm9703404. J Med Chem. 1997. PMID: 9379433

9

High-throughput nuclear magnetic resonance-based screening.

Hajduk PJ, Gerfin T, Boehlen JM, Häberli M, Marek D, Fesik SW. Hajduk PJ, et al. J Med Chem. 1999 Jul 1;42(13):2315-7. doi: 10.1021/jm9901475. J Med Chem. 1999. PMID: 10395471

10

Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein.

Muegge I, Martin YC, Hajduk PJ, Fesik SW. Muegge I, et al. Among authors: hajduk pj. J Med Chem. 1999 Jul 15;42(14):2498-503. doi: 10.1021/jm990073x. J Med Chem. 1999. PMID: 10411471

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page